[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rsv-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rsv-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,79,107,128,156,181,209,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100582676","phase-3-a-phase-3-study-of-revaccination-in-subsequent-pregnancies-with-bivalent-rsv-vaccine-and-duration-of-protection-of-a-single-dose-100582676",false,"NCT06866405","A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.","Pregnant Participants-Cohort 1 and Cohort 2 Key Inclusion Criteria\n\n* Women aged 18 to 49 who are pregnant, between 24 and 36 weeks along, and expecting one baby without known risks for complications can participate.\n* Had the RSVpreF or Abrysvo vaccine during a previous pregnancy.\n* Had an ultrasound scan at 18 weeks or later during their current pregnancy, with no major fetal problems detected.\n* Based on their medical history, physical check-up, and the doctor's judgment, they are found suitable to join the study.\n* Agrees to let their baby take part in the study and gives their permission.\n* Able to sign a consent form, agreeing to follow the rules and conditions of the study.\n\nKey Exclusion Criteria\n\n* Received any approved or experimental RSV vaccine since their previous pregnancy.\n* Has a pre-pregnancy body mass index (BMI) over 40 kg\u002Fm2.\n* History of a severe bad reaction to a vaccine or a serious allergic reaction (like anaphylaxis) to any ingredient in the study vaccine or a similar vaccine.\n* Current pregnancy problems or issues at the time of giving consent.\n* Previous pregnancy issues or problems at the time of giving consent.\n* Women who are breastfeeding at the time of enrollment\n\nInfant Participants\n\n* Proof that the parent(s) or legal guardian(s) has signed and dated a consent form.\n* Parent(s) or legal guardian(s) must agree to attend scheduled visits and follow the study plan, including laboratory tests and other procedures.\n\nNonpregnant Participants-Cohort 3 Key Inclusion Criteria\n\n* Have already received one dose of the RSVpreF vaccine during their previous pregnancy as part of the Pfizer clinical trial, and the results from that time can be used for this study.\n* Able to sign a consent form, agreeing to follow the rules and requirements of the study.\n\nKey Exclusion Criteria\n\n* Received any approved or experimental RSV vaccine after participating in the Pfizer clinical trial.\n* Taking part in other studies with new drugs within 28 days before giving consent or during the study period.",true,"ALL","0 Years",{"count":20,"type":21},550,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.",[27],"RSV Infection",[29,30,31,32],"Pregnancy","RSV vaccine","RSV","Maternal immunization","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2025-04-16",{"date":41,"type":21},"2028-02-24",{"name":43,"class":44},"Pfizer","INDUSTRY",97,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100419583","rsv-burden-in-outpatient-and-hospital-settings-100419583","NCT04743609","RSV Burden in Outpatient and Hospital Settings","Ambulatory Respiratory Tract Infection Survey, Burden of Respiratory Syncitial Virus in the Era of Covid-19","Oursyn","Inclusion Criteria:\n\n* children under 24 months of age (≤)\n* One of the holders of parental authority signed the consent\n* Patient affiliated to a social security scheme (Social Security or Universal Medical Coverage)\n* Acute purulent otitis media (Paradise Criteria) or otorrhea with or withitout associated bronchiolitis\n\nExclusion Criteria:\n\n* Age \\>24 months\n* Refusal by one of the parents\n* Not affiliated to a social security system\n* Maternal RSV vaccination during the pregnancy of the included child","1 Day","24 Months",{"count":57,"type":21},1900,[59],"NA","Strengthening outpatient low respiratory tract infection surveillance to document the burden of Respiratory Syncytial Virus (RSV)",[27,62,63,64],"Children, Only","Outpatient","Otitis",[31,66,67],"children","otitis with or without concomitant bronchiolitis","2026-03-17",{"date":70,"type":37},"2026-03-19",{"date":72,"type":37},"2021-02-08",{"date":74,"type":21},"2026-12-08",{"name":76,"class":77},"Association Clinique Thérapeutique Infantile du val de Marne","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100630052","phase-2-a-phase-2-study-to-investigate-the-efficacy-and-safety-of-zelicapavir-in-participants-aged-28-days-to-36-months-of-age-infected-with-respiratory-syncytial-virus-100630052","NCT07482657","A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus","Inclusion Criteria:\n\n* Participants diagnosed with RSV infection using an approved diagnostic assay, without known and\u002For documented coinfection with SARS-CoV-2 or influenza\n* Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization\n* In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and restrictions, and the participant is likely to complete the study as planned. The caregiver(s) should be of legal age.\n\nExclusion Criteria:\n\n* Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety.\n* Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded.\n* Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study.\n* Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course of the study, systemic medications that are known to cause immunosuppression other than corticosteroids for \\>5 days.\n* Participant has received an investigational agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.","28 Days","36 Months",{"count":89,"type":21},150,[91],"PHASE2","Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.",[27,31,94],"Respiratory Syncytial Virus (RSV)",[31,66,96,97],"Respiratory Syncytial Virus","Pediatric study","NOT_YET_RECRUITING","2026-03-16",{"date":70,"type":37},{"date":102,"type":21},"2026-07",{"date":104,"type":21},"2026-12",{"name":106,"class":44},"Enanta Pharmaceuticals, Inc",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":78},"100529352","real-world-effectiveness-of-perinatal-rsv-immunoprophylaxis-100529352","NCT06172660","Real-World Effectiveness of Perinatal RSV Immunoprophylaxis","Inclusion Criteria:\n\n* ≤ 12 months of age at the time of presentation for evaluation for an acute respiratory infection (ARI).\n* Documentation of an ARI, which is defined as an acute onset (\\\u003C10 days) illness that includes: At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion OR any one of the following: cough, shortness of breath, difficulty breathing, olfactory disorder, taste disorder, confusion, persistent chest pain, pale, gray, hypoxia, clinical or radiographic evidence of pneumonia or respiratory distress syndrome.\n* Residents of Connecticut\n\nExclusion Criteria:\n\n* Illness duration of \\>10 days at the time of respiratory specimen collection, measured from the date of the first symptom of the current acute illness.\n* Parents\u002Fguardians are not able to provide informed consent\n\nTo be eligible for inclusion in the study as a healthy control, an individual must meet all of the following criteria:\n\n* Immunized against RSV ≤ 12 months of age\n* Residents of Connecticut\n* Match an enrolled case that was a vaccine failure by date of birth (±1 month), sex, and immunoprophylactic agent received (i.e., maternal vaccine vs mAb).","12 Months",{"count":115,"type":21},3750,"OBSERVATIONAL","The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?",[27],"2025-08-08",{"date":121,"type":37},"2025-08-14",{"date":123,"type":37},"2024-10-28",{"date":125,"type":21},"2028-12-30",{"name":127,"class":77},"Yale University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":136,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":78},"100583870","prevention-strategy-for-respiratory-syncytial-virus-rsv-infections-in-infants-in-france-100583870","NCT06881953","Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France","Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants: Maternal Vaccination During Pregnancy or Direct Immunization of Children? A French Online Study","SPIRAV","Inclusion Criteria:\n\n* Age ≥ 18\n* Able to speak and understand French well enough to read and comprehend the information leaflet and the questionnaire\n* Delivery in metropolitan France between October 1, 2024, and January 31, 2025\n* Live-born child\n* Term-born child (37 weeks of gestation or more)\n* No objection to participating in the study\n\nExclusion Criteria:\n\n* Women under legal protection","FEMALE","18 Years",{"count":139,"type":21},400,"Bronchiolitis is a viral lower respiratory tract infection, caused in 50 to 80% of cases by the respiratory syncytial virus (RSV).\n\nAlthough generally mild, RSV bronchiolitis remains the leading cause of infant hospitalizations for acute respiratory distress in Europe. In France, nearly 30% of children under two years of age are affected annually, representing approximately 480,000 cases. RSV bronchiolitis accounts for 2 to 3% of hospital admissions among infants under one year each winter. These situations place a significant burden on pediatric intensive care units and emergency departments, impacting the delivery of care for other pediatric patients and raising concerns among parent and families.\n\nUntil September 2023, RSV lower respiratory tract infection prevention strategies in infants in France were limited to non-pharmacological barrier measures, with a monthly injection of the monoclonal antibody palivizumab (Synagis®) recommended among high-risk infants, particularly those born preterm before 35 weeks of gestation.\n\nAt the end of 2023, a new monoclonal antibody, nirsevimab (Beyfortus®), indicated for passive immunization in the general infant population, received marketing authorization. Administered as a single dose to neonates (from birth) and infants during their first RSV season, nirsevimab demonstrated an estimated efficacy of 76% to 83% in preventing severe RSV bronchiolitis during the 2023-2024 epidemic in France. At the same time, the RSV vaccine Abrysvo® (Pfizer) became available in France since September 2024, following European marketing authorization in August 2023. Administered during the third trimester of pregnancy, this maternal immunization strategy aims to confer passive immunity to neonates (from birth up to six months of age) through transplacental transfer of RSV-specific maternal antibodies.\n\nFor the 2024-2025 RSV season, the national prevention strategy for RSV-related respiratory infections in infants is based on general non-pharmacological measures and, between September 15, 2024, and January 31, 2025, on maternal vaccination (administered between 32 and 36 weeks of gestation) and\u002For direct administration of nirsevimab to neonates.\n\nTo date, no population-based data are available in France regarding maternal adherence to the current RSV prevention strategy for respiratory syncytial virus (RSV) infections in infants. The acceptability of maternal RSV vaccination remains unknown, as well as the factors associated with the choice between the two recommended strategies and the reasons given by pregnant women for their decision.\n\nThe objective of this study is to assess, in population, the adherence of pregnant women to the current RSV infection prevention strategy for infants in France, which has not yet been studied. The study will focus on the method most commonly chosen by women (maternal vaccination with Abrysvo® during pregnancy or administration of nirsevimab (Beyfortus®) to their neonates), aiming to identify the factors associated with the choice of one strategy over the other and to describe the main reasons women give for their decision to either follow or not follow one of the prevention strategies.",[27],[143,144,145,146],"Respiratory syncytial virus","nirsevimab","vaccine","health campaign","2025-06-18",{"date":149,"type":37},"2025-06-24",{"date":151,"type":37},"2025-06-17",{"date":153,"type":21},"2025-12-17",{"name":155,"class":77},"Assistance Publique - Hôpitaux de Paris",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":16,"sex":17,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100580900","phase-1-safety-and-immunogenicity-study-of-revaccination-with-scb-1019t-in-healthy-adults-100580900","NCT06843317","Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults","A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before","Inclusion Criteria:\n\n1. Male and female participants 60-85 years of age at the screening visit and who received AREXVY before.\n2. Individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study procedures.\n3. Individuals willing and able to give an informed consent, prior to screening.\n4. Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator; participants with pre-existing stable medical conditions can be included (a stable medical condition is defined as a disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment).\n\nPlease refer to Protocol for full list of Inclusion and Exclusion criteria.\n\nExclusion Criteria:\n\n1. Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor illness (mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator. For participants with minor illness and\u002For fever at the time of vaccination, Visit 1 may be rescheduled within the allowed time-window.\n2. Recurrent or un-controlled neurological disorders or seizures.\n3. Serious or unstable chronic illnesses\n4. Any history of dementia or any medical condition that moderately or severely impairs cognition\n5. History of a severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study vaccines.\n\nPlease refer to Protocol for full list of Inclusion and Exclusion criteria.","60 Years","85 Years",{"count":166,"type":21},160,[168],"PHASE1","CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.",[27],"2025-05-13",{"date":173,"type":37},"2025-05-14",{"date":175,"type":37},"2025-03-21",{"date":177,"type":21},"2026-06-03",{"name":179,"class":44},"Clover Biopharmaceuticals USA, LLC",5,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":16,"sex":17,"minAge":137,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":78},"100562034","phase-2-rsv-vaccination-in-immunocompromised-patients-100562034","NCT06597916","RSV Vaccination in Immunocompromised Patients.","A Phase-2b Controlled Study to Evaluate the Humoral and Cellular Immune Response and Safety Following One and Two Doses of an Adjuvanted RSV Subunit Vaccine in Immunocompromised Patients Aged 18 Years and Older.","General inclusion criteria\n\n1. Participants who, in the opinion of the investigator, can understand and will comply with the requirements of the protocol.\n2. Participants living in the general community or in an assisted-living facility that provides minimal assistance can be enrolled, such that the participant is primarily responsible for self-care and activities of daily living.\n3. Participants who can give written informed consent prior to study entry and performance of any study-specific procedure.\n4. Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, post-menopause, premenarche, bilateral oophorectomy, or bilateral salpingectomy\n5. Female participants of childbearing potential may be enrolled in the study if the participant has practiced adequate contraception from 1 month prior to first Arexvy vaccination and agreed to continue adequate contraception for at least 1 month after completion of the last study intervention administration, and has a negative pregnancy test on the day of first vaccination prior to vaccine application.\n6. Participants with chronic medical conditions with or without specific treatment are allowed to participate in this study if considered by the investigator as medically stable.\n7. Additional inclusion criteria for \"group 1\":\n\n   7.1. Age ≥18 years at the time of signing the Informed consent form (ICF). 7.2. Diagnosis of a hemato-oncological disease: multiple myeloma including early stage disease or lymphoma in participants medically stable in the opinion of the investigator at study inclusion.\n\n   7.3. Participants without SCT or ≥3 months after autologous SCT until 24 months after SCT. SCT \\>24 months, if they have ongoing immunomodulatory\u002Fsuppressive treatment.\n\n   7.4. Immunosuppressive or modulating medication related to the hemato-oncological disease are allowed.\n8. Additional inclusion criteria for \"group 2\":\n\n   8.1. Age ≥18 years at the time of signing the Informed consent form (ICF). 8.2. Diagnosis of lung cancer ≥ stage 1. 8.3. Ongoing cancer treatment (including chemotherapy and immunotherapy) or initiation planned within 14 days and treatment initiation\u002Fvaccinations preferentially scheduled between treatment cycles.\n9. Additional inclusion criteria for \"group 3\":\n\n   9.1. Age ≥18 years at the time of signing the Informed consent form (ICF). 9.2. Diagnosis of an autoimmune\u002Fchronic inflammatory disease with chronic inflammatory bowel disease (IBD) or rheumatoid arthritis (RA).\n\n   9.3. Treatment with biologicals such as TNF-alpha blocker, anti-CD20, JAK-inhibitors or other biological treatment (combinations with DMARDs, immunomodulators or steroidal or non-steroidal anti-inflammatory drugs are allowed).\n\n   9.4. Stable disease at time of study entry.\n10. Additional inclusion criteria for \"group 4\":\n\n10.1. Age ≥60 years at the time of signing the Informed consent form (ICF). 10.2. Healthy, as established by medical history before entering the study with medically stable\u002Fcontrolled chronic conditions such as diabetes, hypertension or cardiac disease allowed.",{"count":189,"type":21},200,[91],"Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn\u002Fwinter in temperate climate zones. Apart from infants and elderly individuals, patients with underlying substantial respiratory, cardiovascular, endocrinological diseases and immunocompromised patients are at increased risk to develop lower respiratory tract infection (LRTI) requiring intensive care associated with increased mortality. For certain risk groups such as patients after hematologic stem cell transplantation (HSCT) in-hospital mortality may be as high as 70 %. A causally related, RSV specific treatment does not exist and treatment is therefore usually supportive and non-specific.\n\nThe study is aiming to determine if immunocompromised patients benefit from two doses of a RSV subunit vaccine as opposed to one dose. The additional dose will be administered off label.",[27],[194,30,195,196,197,198,199],"RSV prophylaxis","RSV vaccination","RSV immunocompromised","RSV multiple myeloma","RSV lung cancer","RSV IBD","2024-11-25",{"date":202,"type":37},"2024-11-27",{"date":204,"type":37},"2024-09-19",{"date":206,"type":21},"2026-03-31",{"name":208,"class":77},"Medical University of Vienna",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":216,"enrollmentInfo":217,"targetDuration":219,"studyType":116,"phases":4,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":78},"100538067","prevalence-and-impact-of-pertussis-and-rsv-on-asthma-severity-and-control-100538067","NCT06286007","Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control","PRIPASCO","Inclusion Criteria:\n\n* Adult patient (age 18 years and over)\n* Diagnosed with asthma at least one year prior to the date of enrolment.\n* Patients who, in the opinion of the investigator, can and will comply with the requirements of the study protocol for the duration of the follow-up period (e.g. agree to provide samples for testing, able to attend for testing upon asthma exacerbation and\u002For ARI symptoms occurring)\n* Patients who are able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with a prior history of pertussis in the last 12 months\n* Patients with ARI within the 2 weeks prior to enrolment\n* Patients who have another respiratory disease other than asthma, alcohol or drug abuse at the time of being included in the study, or an active oncological disease (patients in treatment or follow-up for oncological disease) or pregnant women.\n* Patients treated with immunosuppressive or immunomodulating agents not related to asthma diagnosis. will be excluded.\n* Patients vaccinated for RSV will be also excluded (NOTE: -Patients that have received an RSV (investigational) vaccine or medicine for any of the above, should be excluded from the study from the beginning. Patients that might be vaccinated in the upcoming years, while the study is still ongoing, can enrol. However, from the moment they receive a vaccine, they should be excluded and no additional data will be collected. Data collected during the study up until the time of vaccination will still be included in the analysis).\n* Patients vaccinated for B. Pertussis during the previous 12 months will be also excluded.\n* Patients who plan to move during the study period will be excluded.","99 Years",{"count":218,"type":21},784,"2 Years","The main objective is to estimate the annual symptomatic incidence of Bordetella pertussis and RSV infections in patients aged 18 years and over with asthma, which will be identified by PCR, for Bordetella pertussis and by PCR for RSV performed at a specific timepoint from onset of symptoms for each symptomatic Acute Respiratory Infection (ARI).\n\nA multicentre prospective cohort study will be undertaken in Spain. Thirty-five centres from different autonomous communities in Spain will participate in the study.\n\nParticipants will be asked to report to the investigator if they experience an asthma exacerbation or symptoms of acute respiratory infection with 2 years follow up",[222,223,27],"Asthma","Pertussis",[222,223,27,225],"Exacerbations","2024-02-29",{"date":228,"type":37},"2024-03-01",{"date":230,"type":37},"2023-12-21",{"date":36,"type":21},{"name":233,"class":77},"Hospital Clinico Universitario de Santiago",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":241,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":78},"100529993","evaluation-of-the-effectiveness-and-impact-of-nirsevimab-administered-as-routine-immunization-100529993","NCT06180993","Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization","NIRSE-GAL","Inclusion Criteria:\n\n* Subjects born in Galicia from April 1st, 2023 and March 1st, 2026\n\nExclusion Criteria:\n\n* No specific criteria has been reported",{"count":242,"type":21},42000,"A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.",[27],{"date":246,"type":37},"2023-12-26",{"date":248,"type":37},"2023-09-25",{"date":250,"type":21},"2026-10-31",{"name":252,"class":77},"Federico Martinón Torres"]